Almost every dispensary in the country sorts its menu into indica, sativa and hybrid. Almost every budtender uses the categories to make a recommendation. And the chemical evidence supporting them is remarkably thin.
This is worth understanding, because the indica vs sativa vs hybrid framework is probably the single most common way consumers make purchasing decisions — and it is not doing what people think it is doing.
Where the Categories Came From
The distinction originated in eighteenth-century botany. Cannabis sativa was described by Linnaeus in 1753 from European hemp. Cannabis indica was described by Lamarck in 1785 from Indian material, which differed in appearance and in psychoactive potency.
The names described plant morphology — height, leaf shape, branching pattern, flowering time — in geographically separated populations. They were never intended to describe effects on humans, and they did not.
The modern usage arrived through cannabis breeding culture in the twentieth century, where the terms drifted from describing plant structure to predicting experience: indica as sedating and physical, sativa as energising and cerebral.
Why It Does Not Hold Up
Three problems, each sufficient on its own.
Nearly everything is a hybrid. Decades of intensive breeding, much of it undocumented and conducted under prohibition, have thoroughly mixed the gene pools. Genetic analysis of commercial cultivars consistently finds that products labelled indica and sativa do not separate into distinct genetic groups. The categories describe an ancestry that no longer exists in any pure form.
The labels do not predict chemistry. Chemical analysis across large sample sets has repeatedly found that indica and sativa labelling does not correlate reliably with cannabinoid or terpene profile. Two products labelled indica can be chemically further apart than one indica and one sativa.
Names are not standardised. There is no registry governing cultivar names. The same name from two producers can be genetically and chemically different material, and there is no authority to appeal to. Genetic verification regularly finds that identically named products from different sources are not the same plant. See cannabis strains and the genetics behind them.
The Myrcene Argument
The most common defence is that indica cultivars are higher in myrcene, and that myrcene above a certain threshold produces sedation.
Two problems. Myrcene content does not track the indica/sativa label consistently across large samples. And the sedation threshold that circulates widely in cannabis marketing does not trace back to a controlled human trial — it is a figure that has been repeated until it acquired the appearance of evidence.
Terpenes are genuinely interesting and genuinely worth measuring. The confident effect claims attached to them run ahead of the research, which is covered honestly in terpenes and the entourage effect.
Why It Persists Anyway
Because it is useful as a communication shorthand, even though it is inaccurate as chemistry.
A customer who says they want “an indica” is usually communicating something real: they want something relaxing, for the evening, not stimulating. A budtender who hears that can make a reasonable recommendation. The category is functioning as a proxy for an intention, and the recommendation may well work.
The problem is that it works unreliably, and it fails silently. When a product labelled indica produces an unexpected effect, the framework offers no explanation — because the label was never carrying the information the customer assumed it was.
What Actually Predicts the Experience
Several things, none of which appear in the indica/sativa label.
The measured cannabinoid profile. Total THC, the THC:CBD ratio, and which minor cannabinoids are present at what levels. A high-THC, low-CBD product behaves differently from a balanced one regardless of category. See cannabinoids explained.
The measured terpene profile. The actual chemistry, not the inherited label.
Route of administration. Inhalation reaches peak effect within minutes and resolves in a few hours. Ingestion takes considerably longer to onset, lasts far longer, and involves different metabolism. This difference is larger than any difference between cultivars — covered in forms of medical cannabis.
Dose. The same product at different doses produces different effects, sometimes in opposite directions.
The individual. Tolerance, physiology, endocannabinoid system variation, expectation and setting. Two people consuming identical material from the same jar can have entirely different experiences — see the endocannabinoid system.
The Better Framework: Chemotypes
Researchers and an increasing number of producers use chemovar or chemotype classification — grouping products by measured chemical profile rather than by inherited category.
A chemotype description looks like: total THC 22%, CBD below 1%, dominant terpenes limonene and caryophyllene. That describes the product. “Sativa-dominant hybrid” does not.
The obstacle is not conceptual. It is that chemotype classification requires the analysis to have been run and the data to be published — which means terpene analysis alongside potency, and a certificate that reaches the customer.
Practical Advice
For consumers: use the category as a rough starting point if you like, but treat the certificate of analysis as the actual information. Track which measured profiles you respond well to rather than which names — names are not consistent, chemistry is. How to check a product properly is in choosing tested cannabis products.
For producers: full chemical profiles are increasingly a differentiator. In a market where potency competition has run its course, a documented chemotype is something to compete on — and it is more defensible than a category label anyone can apply to anything.